Neurothera Labs Engages bullVestor for Investor Relations

Vancouver, British Columbia — April 23, 2026 — Leads & Copy — Neurothera Labs Inc. (TSXV: NTLX) has engaged bullVestor Medien GmbH to assist with its investor awareness marketing campaign.

Neurothera, a clinical-stage biotech company and majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), entered into an investor relations agreement with bullVestor, effective April 23, 2026.

bullVestor will provide marketing and investor relations services to enhance Neurothera's visibility with potential investors. Services include content creation management, keyword optimization, ad groups and display ads, project management, and media distribution.

The total cost for the 6-month period is euro 300,000, commencing on or about the date on which the TSX Venture Exchange (“TSXV”) approves the engagement (the “TSXV Approval”). Euro 150,000 is payable within seven days following the TSXV Approval, with the remaining euro 150,000 payable within 45 days following the TSXV Approval.

bullVestor is an arm’s length party from Neurothera and principally operates out of Austria. As of the date of the press release, neither bullVestor nor its directors and officers own any direct or indirect interest in Neurothera’s securities.

The engagement is subject to TSXV approval.

Neurothera Labs Inc. focuses on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.

bullVestor Medien GmbH, incorporated under the laws of Austria, provides corporate marketing and investor relations services. It is wholly-owned by Helmut Pollinger, its Principal. Neither bullVestor nor its principals have any existing interest, direct or indirect, in the securities of NeuroThera Labs Inc., nor any right or intent to acquire any such interest, other than the compensation payable under the Agreement.

Source: Neurothera Labs Inc.